Abstracts tagged "Inflammation"

Abstract Number: 0149 • ACR Convergence 2023
Impacts of Social Determinants of Health and the Immune System in Adults with Acute-to-Chronic Low Back Pain: An Observational Study
Colleen Burke¹, Michael Brown², Kenneth Taylor², Stephanie Danyluk², Kelley Seebeck² and Adam Goode³, ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Durham, NC
Background/Purpose: Chronic low back pain (cLBP) is common worldwide yet poorly understood due to the combination of biological, psychological, and sociological factors. An individual's social…
Abstract Number: 0553 • ACR Convergence 2023
Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus versus Control Subjects and Associated with Lower 24-hour Blood Pressure
Anastasiia Phothisane¹, Shahensha Shaik¹, Qiong Wu¹, Olivia Posey¹, Sean Davies², Jaya Krishnan¹, David Patrick³, C. Michael Stein¹ and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³Department of Veterans Affairs, Nashville, TN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 2-3-fold increased risk of cardiovascular events. A major risk factor for this is hypertension. We previously…
Abstract Number: 0913 • ACR Convergence 2023
Neutrophils in Patients with Systemic Lupus Erythematosus Show Pronounced Inflammatory Signals
Annie Law¹, Chee Jian Pua², Dianyang Guo³, Chin Teck Ng⁴, Julian Thumboo¹, Andrea Hsiu Ling Low⁵ and Xiubo Fan¹, ¹Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²National Heart Centre, Singapore, Singapore, ³Singapore General Hospital, Singapore, Singapore, ⁴Singapore General Hospital; Duke-NUS Medical School, Singapore, Malaysia, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: IFN response, plasmablasts and neutrophils are three hallmarks of systemic lupus erythematosus (SLE). Studies showed that the netting neutrophils stimulated plasmacytoid dendritic cells to…
Abstract Number: 1148 • ACR Convergence 2023
A Comparative Study of Clinical Phenotype in Relation to NOD2 Sub-genotypes in Yao Syndrome
Ashmia Saif¹, Hafsa Nomani², Frank Hwang², Jie Yang² and Qingping Yao², ¹Stony Brook University Hospital, Syosset, NY, ²Stony Brook University, Stony Brook, NY
Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly designated NOD2-associated autoinflammatory disease. A spectrum of NOD2 mutations have been associated with this disease. Most patients…
Abstract Number: 1713 • ACR Convergence 2023
Prevention of Arthritis Development by Mechanical Unloading Through Inhibition of CCL2 and YAP-mediated Inflammation in the Rat Adjuvant-induced Arthritis Model
Elisa Dalix¹, Mathieu Maalouf¹, Robin Caire², Guillaume Courbon¹, Virginie Dumas³, Sylvie Peyroche¹, Marie-Thérèse Linossier¹, Mireille Thomas¹, Charles-Antoine Arthaud¹, Arnaud Vanden-Bossche¹ and Hubert Marotte⁴, ¹Université Jean Monnet Saint-Étienne, Mines Saint-Etienne, INSERM, Saint-Etienne, France, ²Department of Molecular Medicine, University of Padua School of Medicine, Padua, Italy, ³Laboratory of Tribology and Systems Dynamics, Ecole Nationale d'Ingénieurs de Saint Etienne, Ecole Centrale de Lyon, University of Lyon, Saint-Etienne, France, ⁴CHU Saint-Etienne, Saint-Etienne, France
Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease, characterized by synovitis associated with progressive bone loss and joint degradation. The adjuvant-induced…
Abstract Number: 1778 • ACR Convergence 2023
Role of GITR/GITRL Interaction in Modulating T Helper 9, T Helper 17 and T Regulatory Response in Psoriatic Arthritis
Chiara Rizzo¹, Lidia La Barbera¹, Marianna Lo Pizzo¹, Leila Mohammadnezhad¹, federica Camarda¹, Francesco Dieli¹, Francesco Ciccia² and Giuliana Guggino¹, ¹University of Palermo, Palermo, Italy, ²University of Campania - Luigi Vanvitelli, Naples, Italy
Background/Purpose: The inflammatory process characterizing Psoriatic Arthritis (PsA) is mainly driven by interleukin (IL)-23/IL-17 axis and IL-9 overexpression, in presence of T helper (Th)17 and…
Abstract Number: 2221 • ACR Convergence 2023
Clinical and Molecular Patterns Associated with Persistence of Inflammation in Spondyloarthritis Patients: Unveiling Potential Biomarkers
Lourdes Ladehesa Pineda¹, Ivan Arias de la Rosa², Laura Cuesta-López³, Clementina López Medina⁴, María Ángeles Puche Larrubia⁵, Miriam Ruiz-Ponce³, María del carmen Ábalos Aguilera³, Pedro Ortiz Buitrago³, Yasin Hanaee³, Carlos Perez-Sanchez⁶, Chary López-Pedrera³, Alejandro Escudero-Contreras⁷, Eduardo Collantes Estévez⁸ and Nuria Barbarroja⁹, ¹Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba. Rheumatology service. Cordoba. Spain, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁴Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ⁵Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, ⁶IMIBIC, Córdoba, Spain, ⁷Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain, ⁸Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ⁹University of Cordoba, Córdoba, Spain
Background/Purpose: Chronic inflammation is closely associated with an increased risk of cardiovascular diseases (CVD) through the activation of the immune system and the release of…
Abstract Number: 2570 • ACR Convergence 2023
Thrombosis in Patients with VEXAS Syndrome: A Retrospective Cohort Study
Atefeh Ghorbanzadeh¹, Yael Kusne², Alina Dulau-Florea³, Ruba Shalhoub³, Pedro Alcedo³, Khanh Nghiem³, Marcela Ferrada⁴, alexander hines¹, Sumith Panicker³, amanda ombrello⁵, Kaaren K. Reichard¹, Ivana Darden³, Wendy Goodspeed³, Lorena wilson³, Horatiu Olteanu¹, Terra L. Lasho¹, Daniel Kastner⁶, Kenneth Warrington¹, Abhishek A. Mangaonkar¹, Ronald Go¹, David Beck⁷, Mrinal S. Patnaik¹, Neal S. Young⁸, Katherine R. Calvo³, Ana Casanegra⁹, Peter Grayson¹⁰, Matthew Koster¹, Colin O Wu³, Damon E. Houghton⁹, Bhavisha Patel¹¹, Yogen Kanthi¹² and Emma M. Groarke¹³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Phoenix, AZ, ³National Institutes of Health (NIH), Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁵National Institutes of Health, Rockville, MD, ⁶National Human Genome Research Institute, Bethesda, MD, ⁷New York University, New York, NY, ⁸National Institutes of Health (NIH), Rochester, MD, ⁹Mayo Clinic, Rochester, MD, ¹⁰National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ¹¹National Institutes of Health, Beltsville, MD, ¹²National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, ¹³Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, due to somatic mutations in the UBA1 gene, is an autoinflammatory disorder associated with an increased…
Abstract Number: 0228 • ACR Convergence 2023
A Comprehensive Retrospective Analysis of Polymyalgia Rheumatica in Long COVID Patients at an Academic Medical Center in the Midwest
Hanan Ibrahim¹ and Alireza Meysami², ¹Henry Ford Health System (HFHS), Detroit, MI, ²Henry Ford Health, Detroit, MI
Background/Purpose: Polymyalgia Rheumatica (PMR) is an inflammatory disorder that predominantly affects older adults. Incidence peaks at 70-80 years old [1] and is more common in…
Abstract Number: 0585 • ACR Convergence 2023
The Impact of Impaired Vagus Nerve Activity and Transcutaneous Vagus Nerve Stimulation (tVNS) on Arterial Stiffness in Systemic Lupus Erythematosus (SLE)
Tobias Schmidt¹, Christina Brock², Jesper Fleischer³, Søren Jacobsen¹ and Amanda Hempel Zinglersen¹, ¹Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ²Department of Gastroenterology and Hepatology, Aalborg University Hospital and Clinical Institute, Aalborg, Denmark, ³Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease with an increased risk of atherosclerosis. The development of atherosclerosis in SLE cannot be…
Abstract Number: 0940 • ACR Convergence 2023
A Novel Therapeutic Opportunity in Systemic Sclerosis: The Fibrolytic Activities of a Specialized Macrophage Secretome
Françis Bonnefoy¹, Susanne Behlke² and Sylvain Perruche¹, ¹Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Institute/MedINNPharma, Besançon, France, ²MedINNPharma, Besançon, France
Background/Purpose: Systemic sclerosis (SSc) a complex and rare immune-mediated connective tissue disorder characterized by microvascular damage, inflammatory cell infiltration, and excessive deposition of extracellular matrix…
Abstract Number: 1247 • ACR Convergence 2023
Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial
Hermine Brunner¹, Diego Oscar Viola², Richard Dimelow³, Inmaculada Calvo Penadés⁴, Christel Wilkinson⁵, Juan Cruz Rizo Rodriguez⁶, Alina Boteanu⁷, Sylvia Kamphuis⁸, Kirsten Minden⁹, Gerd Horneff¹⁰, Jordi Anton¹¹, Masaaki Mori¹², Yuichi Yamasaki¹³, Jose Miyar Olaiz¹⁴, Rebecca Marino¹⁵, Andre van Maurik¹⁶, Mohamed Okily¹⁷, Emad Yanni¹⁸ and Paul WIlde¹⁹, ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²CAICI Institute, Pediatric Rheumatology, Santa Fe, Argentina, ³GlaxoSmithKline, Clinical Pharmacology Modelling and Simulation, Stevenage, United Kingdom, ⁴Hospital Universitario y Politécnico La Fe, Pediatric Rheumatology Unit, València, Spain, ⁵GlaxoSmithKline, Clinical Statistics, Stevenage, United Kingdom, ⁶Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, San Luis Potosí, Mexico, ⁷Hospital Universitario Ramón y Cajal, Departamento de Reumatología, Madrid, Spain, ⁸Erasmus University Medical Center, Department of Pediatric Rheumatology, Rotterdam, Netherlands, ⁹Charité Universitätsmedizin Berlin, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany, ¹⁰Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, ¹¹Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, ¹²Tokyo Medical and Dental University Hospital, Department of Lifetime Clinical Immunology, Tokyo, Japan, ¹³Kagoshima University Hospital, Department of Pediatrics, Kagoshima, Japan, ¹⁴GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, ¹⁵GlaxoSmithKline, Safety Evaluation and Risk Management, Durham, NC, ¹⁶GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Clinical Development, ImmunoInflammation, Brentford, United Kingdom, ¹⁸GlaxoSmithKline, Clinical Development, Rockville, MD, ¹⁹GlaxoSmithKline, Clinical Development, Brentford, United Kingdom
Background/Purpose: Belimumab (BEL) is an approved treatment for SLE, in addition to standard therapy. Intravenous (IV) BEL is approved in patients (pts) ≥5 years of…
Abstract Number: 1717 • ACR Convergence 2023
Endothelial Cell Sphingosine 1-Phophate Receptor 1 Restrains VE-cadherin Cleavage and Attenuates Experimental Inflammatory Arthritis
Nathalie Burg¹, Miles Tran², Kevin Wei³, Carl Blobel¹ and Jane Salmon¹, ¹Hospital for Special Surgery, New York, NY, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: In rheumatoid arthritis, inflammatory mediators extravasate from blood into joints via gaps between endothelial cells (EC), but the contribution of ECs to inflammatory arthritis…
Abstract Number: 1779 • ACR Convergence 2023
A Novel Inhibitory Pathway of Synovial Inflammation Exerted by Glucocorticoids and TNF Inhibitors Through LAG-3 Up-Regulation
Smadar Gertel¹, Victoria Furer¹, Ari Polachek¹ and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Tel Aviv, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated condition that results in systemic musculoskeletal (MSK) inflammation, including peripheral synovitis, enthesitis and axial involvement. Glucocorticoids (GCs)…
Abstract Number: 2238 • ACR Convergence 2023
Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
Arthur Kavanaugh¹, Enrique Soriano², Jan Dutz³, Carlo Selmi⁴, Emmanouil Rampakakis⁵, Natalie shiff⁶, Francois Nantel⁷, Frederic Lavie⁸ and Laura Coates⁹, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Department of Dermatology and Skin Science, Vancouver General Hospital, Vancouver, BC, Canada, ⁴Rheumatology and Clinical Immunology, Humanitas Research Hospital / Internal Medicine, Humanitas University, Rozzano, Italy, ⁵McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁶Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁷Nantel Medsci Consult, Consultant, Montreal, QC, Canada, ⁸The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁹University of Oxford, Oxford, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) has been associated with an increased risk of cardiovascular (CV) disease, likely due to accelerated atherosclerosis secondary to chronic inflammation.1 As…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].